The US market says otherwise @imback.
Those are serious analysts who are unpacking the data and they've got more money and clout than you.
- Forums
- ASX - By Stock
- MSB
- Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
MSB
mesoblast limited
Add to My Watchlist
2.61%
!
$2.36

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-502
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.36 |
Change
0.060(2.61%) |
Mkt cap ! $3.020B |
Open | High | Low | Value | Volume |
$2.29 | $2.37 | $2.27 | $5.647M | 2.423M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
31 | 67376 | $2.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.36 | 104388 | 29 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
31 | 67376 | 2.350 |
38 | 100133 | 2.340 |
23 | 184302 | 2.330 |
14 | 84402 | 2.320 |
21 | 233668 | 2.310 |
Price($) | Vol. | No. |
---|---|---|
2.360 | 104388 | 29 |
2.370 | 102873 | 31 |
2.380 | 170278 | 25 |
2.390 | 201366 | 19 |
2.400 | 320858 | 17 |
Last trade - 14.17pm 18/09/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |